Artikel ; Online: 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us.
Multiple sclerosis and related disorders
2023 Band 71, Seite(n) 104563
Abstract: Background: Rituximab (RTX) is largely used as a long-term maintenance therapy in various inflammatory neurological diseases. Reducing the dose of maintenance therapy of RTX from 2 grams every 6 months (traditional regimen) to 1 gram every 6 months ( ... ...
Abstract | Background: Rituximab (RTX) is largely used as a long-term maintenance therapy in various inflammatory neurological diseases. Reducing the dose of maintenance therapy of RTX from 2 grams every 6 months (traditional regimen) to 1 gram every 6 months (reduced regimen) is a widely applied practice, with the assumption that it decreases the risk of side effects while maintaining efficacy. Methods: In order to better describe the biological consequences of this strategy, we retrospectively compared, in a single center, the B-cell count after the traditional regimen and after the reduced regimen in patients who underwent both (n = 161). Results: The rate of patients with B-cell repopulation was not significantly different between traditional and reduced regimens (9.9% vs 15.6%, p = 0.18). Among the 145 patients who did not have B-cell repopulation following the traditional regimen, B-cell repopulation following the reduced regimen occurred in only 16 cases (11.0%) and was usually slight: 11/16 patients had only 1% of CD19+ cells. Conclusion: These data emphasize the relevance of 1 g of RTX as maintenance therapy and the fact that 2 g of RTX is generally an overtreatment in inflammatory neurological diseases. |
---|---|
Mesh-Begriff(e) | Humans ; Rituximab/adverse effects ; Neuromyelitis Optica/drug therapy ; Neuromyelitis Optica/chemically induced ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/chemically induced ; Immunologic Factors/adverse effects ; Retrospective Studies |
Chemische Substanzen | Rituximab (4F4X42SYQ6) ; Immunologic Factors |
Sprache | Englisch |
Erscheinungsdatum | 2023-02-10 |
Erscheinungsland | Netherlands |
Dokumenttyp | Journal Article |
ZDB-ID | 2645330-7 |
ISSN | 2211-0356 ; 2211-0348 |
ISSN (online) | 2211-0356 |
ISSN | 2211-0348 |
DOI | 10.1016/j.msard.2023.104563 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.